Table 3.
Common adverse events observed in selected key clinical trials of FGFR inhibitors.
| FGFR Inhibitor | Study | Hyperphosphatemia | Diarrhea | Fatigue | Stomatitis | Ocular Side Effects | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 | ||
| Erdafitinib | Loriot et al. [23] (n = 99) Phase 2 |
75% | 2% | 46% | 4% | 30% | 2% | 47% | 10% | Dry eyes-18% Blurred vision-17% |
Dry eyes-1% |
| Soria et al. [47] (n = 11) Phase 1 |
64% | - | - | - | 45% | - | 64% | 18% | - | - | |
| Pemigatinib | Abou-Alfa et al. [24] (n = 145) Phase 2 |
55% | 0% | 34% | 3% | 31% | 1% | 27% | 5% | Dry eyes-21% Keratitis-1% |
Dry eyes-1% Keratitis-1% |
| Infigratinib | Javle et al. [25] (n = 71) Phase 2 |
56% | 16% | 12% | 3% | 33% | 3% | 24% | 6% | Dry eyes-21% | - |
| Derazantinib | Mazzaferro et al. [48] (n = 29) Phase 1/2 |
66% | 10% | 21% | - | 35% | - | - | - | Eye toxicities *-34% | Eye toxicities *-7% |
* Eye toxicities include blepharitis, dry eyes, blurred vision, diplopia, keratitis, and corneal disorder. Dose interruption and reduction due to eye toxicity: 24%.